<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374020</url>
  </required_header>
  <id_info>
    <org_study_id>BNZ-0077-017</org_study_id>
    <nct_id>NCT03374020</nct_id>
  </id_info>
  <brief_title>Retinal Imaging Using NOTAL-OCT</brief_title>
  <official_title>Retinal Imaging Using NOTAL-OCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notal Vision Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notal Vision Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison between retinal measurements, done by the Notal-OCT imaging and a commercial OCT&#xD;
      (Optical Coherence Tomography)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 14, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The level of agreement between NOTAL-OCT and commercial OCT in detecting fluid in the 10 central degrees of the macula.</measure>
    <time_frame>1 year</time_frame>
    <description>OCT B-scans from both devices will be graded for fluid by an eye care professional and results per macula will be analyzed. A binary decision &quot;there is fluid&quot; or &quot;there is no fluid&quot; will be given to each macula (10 central degrees). Then agreement between decisions, commercial and Notal OCT, will be compared</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Intermediate AMD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced AMD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>DR without macular edema</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>DR with macular edema</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Notal OCT</intervention_name>
    <description>Imaging using Notal OCT</description>
    <arm_group_label>Advanced AMD</arm_group_label>
    <arm_group_label>DR with macular edema</arm_group_label>
    <arm_group_label>DR without macular edema</arm_group_label>
    <arm_group_label>Intermediate AMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. AMD population - intermediate and advanced AMD (with active and non-active CNV)&#xD;
&#xD;
          2. DR population. Patient with and without DME&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability and agreement to give informed consent (IC)&#xD;
&#xD;
          2. Diagnosis of AMD or DR in SE by OCT&#xD;
&#xD;
          3. Ability to undergo OCT scans&#xD;
&#xD;
          4. VA of 20/160 or better in SE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AMD and DR in the same SE&#xD;
&#xD;
          2. Evidence of macular disease other than AMD or DME in SE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

